$EWTX

Edgewise Therapeutics (EWTX) announced preclinical data showing its cardiac sarcomere modulator EDG-7500 improves cardiac relaxation while preserving systolic function. The company will host a webcast to discuss these findings. EDG-7500 is being evaluated for hypertrophic cardiomyopathy (HCM) and a Phase 3 trial is expected to begin in Q4 2026. Early clinical observations align with preclinical data, and a peer-reviewed publication is set to release.

Edgewise Therapeutics (EWTX) saw significant options activity, with a 6,000-contract diagonal spread indicating a bullish stance. Traders rolled ITM Sep $45 calls to OTM Oct $50 calls, targeting an 8.4% rally. EWTX stock is up 197% over the past year, driven by a $2.65B business sale. Analysts have mixed views on its valuation and profitability.

Russell Alan J (Chief Scientific Officer) sold 5,901 shares of Edgewise Therapeutics, Inc. (EWTX) at an average of $43.73 ($43.68–$44.46, $0.26M total) across 3 trades on 2026-08-12.

MOORE JOHN R (General Counsel) sold 5,016 shares of Edgewise Therapeutics, Inc. (EWTX) at an average of $43.82 ($43.80–$44.50, $0.22M total) across 4 trades on 2026-08-12.

Derakhshan Behrad (Chief Business Officer) sold 5,100 shares of Edgewise Therapeutics, Inc. (EWTX) at an average of $43.81 ($43.70–$44.50, $0.22M total) across 4 trades on 2026-08-12.

KOCH KEVIN (President and CEO) sold 17,971 shares of Edgewise Therapeutics, Inc. (EWTX) at an average of $43.68 ($43.64–$44.33, $0.79M total) across 3 trades on 2026-08-12.

Edgewise Therapeutics (Nasdaq: EWTX) reported Q2 2026 results and said its EDG-7500 12-week Phase 2 CIRRUS-HCM trial showed positive top-line data in obstructive and nonobstructive HCM, with Phase 3 planned for Q4 2026. In July 2026, it completed selling sevasemten and its muscular dystrophy business to Servier for $1.55B upfront plus up to $1.1B milestones. Q2 cash was about $460.7M; net loss was $57.3M.

Edgewise Therapeutics, Inc. (EWTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 News Release Edgewise Therapeutics Reports Second Quarter 2026 Financial Results – Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) – – Completed sale of sevasemte

Edgewise Therapeutics Inc. (Nasdaq: EWTX) said it has closed the sale of its muscular-dystrophy business to France’s Les Laboratoires Servier. The transaction includes a drug pipeline led by sevasemten and could be worth up to $2.65 billion, according to the company.

Servier completed its acquisition of Edgewise Therapeutics’ muscular dystrophy business for up to $2.65 billion, including $1.55 billion upfront and up to $1.1 billion in regulatory and commercial milestones, after regulatory clearance. The deal adds sevasemten, in a pivotal Becker muscular dystrophy cohort and Phase 2 Duchenne study. (EWTX)